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The results obtained in the treatment of early syphilis with penicillin have been
presented by the writers in previous reports (1, 2). In the previous studies, totals
of 1.2 million and 2.4 million units, respectively, were administered in treatment
schedules which utilized a three-hour interval between injections. The results
were not considered to be the best obtainable with penicillin therapy. Subse-
quent to the publication of the above reports, studies of concentration of peni-
cillin in blood serum (3) indicated that a two-hour interval between injections
was more efficacious than a three-hour interval in maintaining a uniform blood
level.
The present report covers an observation period of six to thirty months for a
large series of patients treated for early syphilis with a penicillin schedule which
employed a two-hour interval between injections. The treatment schedule con-
sisted of 40,000 units of sodium penicillin administered by intramuscular injec-
tiois at two hour intervals for a total of 85 injections (3,400,000 units). Com-
mercial penicillin products of various manufacturers were used. Reactions to
this therapy (except for the usual therapeutic shock, i.e., Herxheimer) were not
frequent or severe, and in no instance was it found necessary to discontinue
treatment before the completion of the prescribed course.
A total of 728 unselected patients, predominantly young white males, in whom
an unequivocal diagnosis of early syphilis was established, were treated. Ap-
proximately 67 per cent displayed only the primary lesion of syphilis; the re-
mainder presented skin, mucous membrane, or glandular manifestations of the
secondary phase of the disease. All clinical diagnoses were confirmed by labora-
tory findings. So far as is known, no other antisyphilitic therapy was received
by any of the patients. A diligent effort was made to obtain post-treatment ob-
servations at weekly or bi-weekly intervals during the first six months.
Table I displays the social data and clinical status at the time of treatment of
the patient group.
After the disappearance of clinical evidence of the disease, acceptance of con-
tinued satisfactory response to therapy was based upon serologic reactions. The
serologic routine consisted of seven distinctive tests, namely, Kahn, Kline (Diag-
nostic and Exclusion), Hinton, Eagle, and Mazzini flocculation tests, and the
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Kolmer complement fixation method. In addition, end-point quantitative sero-
logic determinations were carried out with two of the flocculation methods, Kahn
and Mazzini.
In patients satisfactorily responding to penicillin therapy, the anticipated sero-
logic curve consists of a gradual and progressive decline in the titer of the quanti-
tative reactions, followed by reversal to negative in the findings of all test pro-
cedures. The term "negative", as employed in the present report, may be con-
strued as indicating negative findings in all tests. An exception has been made
for patients having a plus-minus and/or a one-plus Mazzini or Kline Exclusion
reaction which are also considered negative.
The term "improved" is employed to designate patients in whom the trend of
the serologic curve has been consistently downward but has not reached the nega-
TABLE I
Clinical and social data on 7J8 patients treated with 40,000 units penicillin
given every two hours for 85 injections
PaIMARY (485) sEco,m.ay (243)
AGE oaom' Male Female Male Female
White Colored White Colored White Colored White Colored
Years
20 or less 79 16 1 1 28 9 1 2
21—25 137 31 4 1 42 23 6 1
26—30 74 16 2 32 11 3 1
31—35 40 6 1 27 12 1
36—40 21 9 1 15 4
41—45 23 3 12 1
46—50 13 1 7
51—55 3 1 2 1
56—60 1 1
61—65 1.
Total 391 83 9 2 166 62 11 4
tive phase at the time of report. In instances in which seronegativity was found
to exist after a long lapse from post-treatment observation, no effort was made to
estimate the probable time at which the negative state was attained. This
accounts for some patients being carried in the "unchanged" or "improved" cate-
gory for a year or longer, prior to being classed as seronegative.
The term "serologic relapse" designates a sustained increase in titer after a de-
cline following treatment.
The clinical and serologic status of the patients at the completion of the
monthly periods of post-treatment observations are displayed in Table II. The
table also contains the broad classification accorded the patients in whom re-
treatment was carried out and a compilation of the cumulative failure, or re-
treatment, rate. The latter device represents a statistical attempt to give weight
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TABLE II
Observations on Z88 patients with early syphilis treated with 40,000 units of penicillin
given every two hours for 85 injections
(Total Dosage—3,400,000 units)
NOT RE- 02
RE-TREATED TREATED
DURATION 53
OBSERVATION Unchanged or Negative Z n o o
N N si Improved serologic — .2 .!i 0 3 z 3i.1 serologic status status o
N 2. M Nh Nh(days)
A B C D E F G H I J K L M N
num- per num- per6cr cent 6cr cent
1— 30 728 71.3 519 492 94.80 27 5.20 0.00 100.00 100.00 0.00
31— 60 728 70.7 515 442 85.83 73 14.17 0.00 100.00 100.00 0.00
61— 91 728 66.6 485 372 76.70 111 22.89 1 0.41 99.59 99.59 0.41
92—121 728 63.7 464 304 65.52 157 33.84 3 0.65 99.35 98.94 1.06
122—151 728 60.0 437 261 59.73 174 39.82 2 0.46 99.54 98.48 1.52
152—182 728 55.8 406 223 54.93 181 44.58 2 0.49 99.51 98.00 2.00
183—212 728 51.2 373 181 48.53 192 51.47 0.00 100.00 98.00 2.00
213—242 721 46.3 334 149 44.61 184 55.09 1 0.30 99.70 97.71 2.29
243—273 696 42.7 297 129 43.43 168 56.57 0.00 100.00 97.71 2.29
274—303 648 40.9 265 108 40.75 156 58.87 1 0.38 99.62 97.34 2.66
304—333 584 39.6 231 89 38.53 141 61.04 1 0.43 99.57 96.92 3.08
334—365 530 39.2 208 68 32.69 139 66.83 1 0.48 99.52 96.45 3.55
366—395 461 38.4 177 56 31.64 121 68.36 0.00 100.00 96.45 3.55
396—425 419 38.4 161 42 26.09 117 72.67 2 1.24 98.76 95.25 4.75
426—456 395 34.2 135 28 20.74 106 78.52 1 0.74 99.26 94.55 5.45
457—486 331 31.7 105 23 21.90 82 78.10 0.00 100.00 94.55 5.45
487—516 264 36.0 95 20 21.05 75 78.95 0.00 100.00 94.55 5.45
517—547 220 35.9 79 15 18.99 63 79.75 1 1.27 98.73 93.35 6.65
548—577 178 37.6 67 13 19.40 54 80.60 0.00 100.00 93.35 6.65
578—607 148 38.5 57 11 19.30 46 80.70 0.00 100.00 93.35 6.65
608—638 126 31.7 40 4 10.00 36 90.00 0.00 100.00 93.35 6.65
639—668 112 27.7 31 1 3.23 30 96.77 0.00 100.00 93.35 6.65
669—698 101 25.7 26 26 100.00 0.00 100.00 93.35 6.65
699—730 85 24.7 21 21 100.00 0.00 100.00 93.35 6.65
731—912 69 20.3 14 14 100.00 0.00 100.00 93.35 6.65
1 Percentages based on number of patients observed in each period.
2 Calculated by a statistical device to give weight to the probable failures which may
have taken place among those patients lost from observation.
to the probable failures which may have taken place in that portion of the treat-
ment group which was lost from observation; it is computed on the basis of the
number of observatiors in each time period in relation to the number of failures
or re-treatments for any reason, up to and including that time period.
In column C of Table II are displayed the percentages of total patients followed
in each of the post-treatment observation periods. The initial loss of 30 per cent
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of the patient material through failure to obtain any follow-up is regrettable and
may be due, in part, to the uncertainties of residence inherent in the seafaring
occupations of the majority of the group.
Columns E, F, G and H portray the serologic status of the patients at the
various post-treatment periods. In columns I and J are listed the patients who
were re-treated. Patients who displayed any clinical evidence of recurrent early
syphilis are grouped together, because of the lack of a satisfactory means of
differentiating clinical relapse and reinfection.
Columns K and N are devoted to the observed and the cumulative re-treatment
rates.
Not displayed in the above tables are the results of spinal fluid examinations.
Pretreatment spinal fluid examinations were carried out for 492 patients. The
laboratory procedures employed consisted of the Koliner complement fixation
test, the Eagle flocculation test, cell count, total protein determination, and the
colloidal gold reaction. Of the total examinations, negative findings were re-
corded in fluid from 458 patients. In 34 instances there were some deviations,
usually slight, from an arbitrarily selected normal in one or more of the test
methods employed. None of the patients displayed clinical evidence of central
nervous system involvement.
Post-treatment spinal fluid examinations, six months or more following the com-
pletion of therapy, were carried out for 230 patients, of whom 162 were individu-
als who had had pretreatment spinal fluid studies. Post-treatment spinal fluid
examinations were negative except in three instances. These fluids were from
patients whose pretreatment examination had been positive, but neither the pre-
treatment nor post-treatment changes were associated with evidence of brain-stem
involvement.
DISCUSSION
.Arnong the 728 patients who comprised the clinical material, 17 of those re-
maining under observation were re-treated for clinical or serologic reasons; 14 of
the 17 re-treated patients displayed clinical evidence of early syphilis. Almost
unimpeachable evidence of reinfection was present in some instances, but because
of the lack of accurate diagnostic criteria, a differentiation between clinical re-
lapse indicating failure of the therapy, and reinfection indicating success of the
initial treatment, is not attempted.
The data displayed in columns D through H of Table II show the ratios which
exist in each observation period between the total number of patients observed
and the number which attained seronegativity. These ratios indicate a con-
sistent trend toward the negative phase as the duration of the post-treatment
period lengthens.
The tendency for the majority of unsatisfactory results to become apparent
during the initial six months of the post-treatment period is reflected in columns
I and J of Table II. The same characteristic has been observed in previous peni-
cillin studies.
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Frequencyand regularity of post-treatment quantitative serologic examinations
are essential to the accurate portrayal of the serologic curve. Irregularity in the
spacing of the observations and long lapses from observation tend to distort the
serologic picture and render difficult the proper interpretation of residual
positivity. In' the present report no attempt has been made to estimate the
probable date of seroreversal in patients found to be seronegative after a long
lapse from observation.
Although more uniform penicillin blood levels are attainable through the in-
jection of the antibiotic at two-hour intervals, the inference that the results ob-
tained in the present series may be attributed to the employment of a two-hour
period, is not justified. No comparable studies are available in which a total of
3.4 million units or more of the antibiotic has been employed in the treatment of
early syphilis and in which the interval between injections has been three hours
or more.
Although not a part of the present report, the response of the re-treated
patients to the same or increased amounts of penicillin is interesting. In each
instance in which the patients remained under observation for adequate periods
of time, the clinical and serologic behavior was similar to that observed in patients
responding to initial therapy in a satisfactory manner.
Whether the minimal changes which were recorded in both pretreatment and
post-treatment spinal fluid examinations are indicative of changes in the fluid it-
self, or are expressions of the inconsistencies and vagaries which are inherent in
the test methods themselves, cannot be stated. Because all the patients with
abnormal pretreatment spinal fluid findings failed to develop symptoms referable
to central nervous system involvement, and because the findings in nine of twelve
fluids from these patients were completely normal on post-treatment testing, it
does not appear warranted to base a diagnosis of asymptomatic neurosyphilis
upon the type of changes which were observed in the present series.
The cumulative failure or re-treatment rate is computed on the basis of the
number of observations made in each time period in relation to the number of
failures or re-treatments for any cause. This type of analysis becomes hyper-
critical in instances in which failures occur in a time period in which there has
been a limited number of patients observed.
CONCLUSIONS
1. A therapy consisting of 40,000 units of penicillin administered at two-hour
intervals for a total of 85 injections was employed in the treatment of 728 patients
with the confirmed diagnosis of early syphilis.
2. Clinical and serologic consideration led to the re-treatment of 17 individuals
up to the present.
3. Of the patients re-treated 14 displayed clinical evidence of early syphilis.
No effort is made to differentiate between clinical relapse and reinfection. In
three instances re-treatment was dictated by serologic relapse or serologic
failure.
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4. An increasing proportion of patients in each treatment period attained sero-
negativity as the duration of the post-treatment period lengthened.
5. No confirmed instances of central nervous system involvement were noted.
DISCUSSION
Dr. Charles Rein: It is indeed a great honor for all of us to hear this timely report from the
man who discovered and first described the value of penicillin therapy in syphilis. His
excellent presentation will give additional confidence to the dermatologist and syphilologist
in the treponernacidal efficacy of this antibiotic. Some recent publications describe failures
up to 30% with penicillin in early syphilis. Dr. Romansky and I reported on the treatment
of early syphilis with calcium penicillin-oil-beeswax and our proven failure rate was
almost identical with that obtained by Doctors Mahoney and Arnold. It is our belief that
many of the so called failures reported by other investigators are not true relapses. At the
New York City Board of Health and New York skin and Cancer Unit of the New York Post.
graduate Medical School and Hospital we have started a study on the treatment of early
syphilis with single daily injections of crystalline penicillin Gin peanut oil and beeswax for
sixteen days. The patients receive 300,000 units of penicillin a day for a total of 4.8 million
units. The preliminary clinical and serologic results so far are most encouraging. Dr.
Rosenthal is here today and he may wish to make some comments regarding this study. I
want to take this opportunity to congratulate Doctors Mahoney and Arnold for their excel-
lent and most interesting paper.
Dr. Theodore Rosenthal: May I also express my deep appreciation and admiration for this
paper? The work to which Dr. Rein alluded is an attempt to arrive at a practical ambula-
tory treatment for syphilis. Dr. Mahoney's treatment consists of penicillin dissolved in
saline and given at intervals of 2 to 3 hours around the clock, whereas the physician in prac-
tice requires a simplified method such as penicillin in an absorption-retarding medium which
need be injected only once a day. This work being carried on at the New York City Health
Department in conjunction with the New York Skin and Cancer Unit has been under way
for only a few months, so that definitive results cannot as yet be reported. However, it is
very encouraging and promising. On the other hand, I do not believe that these prepara-
tions are the final answer, because oily mixtures themselves are not completely satisfactory
for a number of reasons. It is hoped that in the near future better mixtures for the retarda-
tion of penicillin on intramuscular injection will be developed, so that the ideals of Dr.
Mahoney may approach realization.
Dr. John H. Stokes: I am sorry to have been too late to hear Doctor Mahoney's presenta-
tion although I have heard him many times in the past; but it was a pleasure to hear the
discussors. I agree with what Dr. Rein said, that the criteria for judgment on whether or
not patients have failed to achieve a cure on serologic criteria are getting weaker and
weaker, and that the question of specificity of tests and reinfection versus relapse is becloud-
ing the issue. I think that the long-time data will be definitely superior, and personally I
would say that the treatment I would take were I personally infected with syphilis, is peni-
cillin, and penicillin alone at the start.
Dr. Joseph V. Klauder: I should like to ask Dr. Mahoney what was the latest period in the
early syphilis cases that he started treatment; was it in the frank secondary stage, or late
secondary? It is easy to formulate treatment, but most difficult to carry it out. For
example, Dr. Rein just mentioned patients who report for 2 or more years. That entails
considerable emotional strain on the patient, reporting every morth for 2 years for sero-
logic tests, and being told that the test is not yet negative, and that further treatment is
still being withheld. There is a difference between scientific formulas for treatment of
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syphilis and the art of practicing medicine. The patient must be treated as well as
the disease.
Dr. Waiter Lever: I should like to ask Dr. Mahoney how soon he permits patients to get
married or to have sexual exposure?
Dr. H. N. Cole (Cleveland): I have nothing but the greatest admiration for the work of
Dr. Mahoney and his coworkers, and feel that in a way much of the credit for this work with
penicillin in the treatment of syphilis has slipped away from the men who originally brought
it out.
Dr. Mahoney: I appreciate the very kind expressions of the discussors.
As regards the question of Doctor Klauder concerning the stage of syphilis at the time of
treatment, 65 per cent of the patients were in the primary stage, and 35 per cent had passed
into the secondary stage.
As to sanctioning marriage and unprotected sexual exposure, a difficult problem is always
presented. Generally, it may be stated that unprotected sexual exposure should not be
approved for a period of at least six months following the healing of the lesion.
As to sanctioning marriage, we are guided by the character of the serologic curve. We
feel very weak in not being able to be more precise in this matter, but it is the situation
which exists at the present state of our knowledge.
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